A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 60 Years and Above
Latest Information Update: 21 Apr 2023
Price :
$35 *
At a glance
- Drugs 202-CoV (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Shanghai Zerun Biotechnology Co
- 18 Apr 2023 Planned End Date changed from 1 Oct 2023 to 1 Jun 2023.
- 18 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2022 New trial record